Suspected adverse drug reactions of rivaroxaban reported in the United States food and drug administration adverse event reporting system database: a pharmacovigilance study

Similar Items

• Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
  by: Yamin Shu, et al.
  Published: (2023-05-01)
• A real-world pharmacovigilance study of KRAS G12C mutation inhibitors based on the food and drug administration adverse event reporting system
  by: Lisha Wu, et al.
  Published: (2024-08-01)
• Disproportionality analysis of drug-induced dry mouth using data from the United States food and drug administration adverse event reporting system database
  by: Dan Xu, et al.
  Published: (2024-10-01)
• Cardiovascular Toxicities of Ibrutinib: A Pharmacovigilance Study Based on the United States Food and Drug Administration Adverse Event Reporting System Database
  by: Yi Zheng, et al.
  Published: (2023-01-01)
• Drug-induced coagulopathies: a real-world pharmacovigilance study using the FDA adverse event reporting system
  by: Yanjun Lu, et al.
  Published: (2024-12-01)